BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» University of California Oakland and 1200 Pharma jointly develop GTPase KRAS inhibitors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
University of California Oakland and 1200 Pharma jointly develop GTPase KRAS inhibitors
June 9, 2023
No Comments
Research at the University of California, Oakland and 1200 Pharma LLC has led to the identification of GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
BioWorld Science
Cancer
Patents